Analysts Set Polaryx Therapeutics, Inc. (NASDAQ:PLYX) PT at $7.67

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $7.6667.

Several equities research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Polaryx Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright assumed coverage on shares of Polaryx Therapeutics in a report on Thursday, July 9th. They issued a “buy” rating and a $7.00 price target on the stock. Zacks Research upgraded shares of Polaryx Therapeutics to a “hold” rating in a research report on Friday, July 10th. Weiss Ratings raised shares of Polaryx Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Wednesday, July 1st. Finally, Raymond James Financial began coverage on shares of Polaryx Therapeutics in a research report on Thursday, August 13th. They issued a “strong-buy” rating and a $6.00 target price for the company.

Polaryx Therapeutics Price Performance

Shares of NASDAQ PLYX opened at $2.01 on Monday. The stock’s 50-day simple moving average is $2.18 and its two-hundred day simple moving average is $3.45. Polaryx Therapeutics has a twelve month low of $1.85 and a twelve month high of $48.91. The firm has a market capitalization of $100.20 million and a P/E ratio of -25.12.

Polaryx Therapeutics (NASDAQ:PLYX) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.02. As a group, research analysts anticipate that Polaryx Therapeutics will post -0.22 EPS for the current fiscal year.

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.